血浆miR-21、miR-155水平对胰腺癌的诊断价值

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (652 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression and clinical significance of microRNA (miR)-21 and miR-155 in plasma of patients with pancreatic cancer. Methods A total of 88 patients with pancreatic cancer treated in Shijiazhuang First Hospital from April 2017 to May 2019 were selected as the the pancreatic cancer group, 40 cases of chronic pancreatitis were treated as chronic pancreatitis group, and 40 healthy subjects were treated as healthy control group. Fluorescence quantitative PCR (qRT-PCR) was used to detect the expressions of miR-21 and miR-155 in plasma samples of the three groups, and the relationship between the expressions of miR-21 and miR-155 in plasma and clinicopathological features was analyzed in patients with pancreatic cancer. The subject operating characteristic curve was used to analyze the diagnostic value of plasma miR-21, miR-155 and the combined detection for pancreatic cancer. Results The expressions of serum miR-21 and miR-155 in the pancreatic cancer group were significantly higher than those in the chronic pancreatitis group and the healthy control group (all P ＜ 0.05). The expressions of miR-21 and miR-155 in the serum of patients with different tumor differentiation and TNM stage pancreatic cancer were statistically significant (all P ＜ 0.05). There were no statistically significant differences in the expressions of miR-21 and miR-155 in the serum of pancreatic cancer patients with different gender, age, tumor diameter, tumor location, pathological type or whether accompanied by lymph node metastasis (all P ＞ 0.05). The diagnostic value of combined detection of miR-21 and miR-155 was higher than that of any single indicator (all P ＜ 0.05). Conclusion The expressions of miR-21 and miR-155 are increased in patients with pancreatic cancer, and their expression is related to tumor pathological stage and pathological grade. Combined detection of plasma miR-21 and miR-155 has a high diagnostic value in pancreatic cancer.

Key words： MicroRNA-21 MicroRNA-155 Pancreatic cancer Diagnosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xin1 FENG Jin1 GUAN Xing1 DU Meijuan2 MENG Ning3 ZHANG Yubin3

Cite this article:

LI Xin1 FENG Jin1 GUAN Xing1 DU Meijuan2 MENG Ning3 ZHANG Yubin3. Diagnostic value of plasma miR-21 and miR-155 levels in pancreatic cancer[J]. 中国医药导报, 2020, 17(20): 21-24.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I20/21

[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Zhang HD，Jiang LH，Sun DW，et al. The role of miR-130a in cancer [J]. Breast Cancer，2017，24（4）：521-527.
[3] 董文珠，陈杭萍，陈赛贞，等.miRNA-628-3p调控乳腺癌细胞增殖的作用及机制研究[J].重庆医学，2019，48（18）：3082-3086.
[4] 郭梦玲，王熙才，陈艳.miRNA在肺癌发生发展中的作用及其机制的研究进展[J].中国肿瘤生物治疗杂志，2019， 26（11）：1281-1287.
[5] 苏俊玲，乌云，杨文静，等.miR-21通过负调节CYLD表达促进宫颈癌增殖[J].中国生育健康杂志，2019，30（6）：534-540.
[6] Al-Haidari AA，Syk I，Thorlacius H. MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA [J]. Oncotarget，2017，8（9）：14887-14896.
[7] 白雪莉，马涛，梁廷波.美国癌症联合委员会第8版胰腺癌分期系统更新简介及解读[J].中国实用外科杂志，2017，37（2）：146-148.
[8] 孙玲，赵智强.84例中晚期胰腺癌的中医病机证素探析[J].国际中医中药杂志，2016，38（5）：400-402.
[9] 张涛.中药单体及有效成分治疗胰腺癌的实验研究进展[J].国际中医中药杂志，2019，41（11）：1270-1273.
[10] 张贤彬，董鑫，闫玉梅，等.手术联合辅助治疗与单纯手术治疗可切除胰腺癌临床疗效的Meta分析[J].中华消化外科杂志，2017，16（12）：1222-1228.
[11] 秦牛，周鑫，杨晓俊，等.CA19-9及CA72-4联合检测在胰腺癌诊断中的应用价值[J].现代生物医学进展，2019，19（23）：4463-4465，4495.
[12] 张波，邹莉.MiR-21对乳腺癌诊断价值的Meta分析[J].标记免疫分析与临床，2019，26（6）：921-926.
[13] 陶新路，丁伯应.miR-21在非小细胞肺癌中的研究进展[J].世界最新医学信息文摘，2019，19（86）：84-86.
[14] Wang P，Chen D，Ma H，et al. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis [J]. Onco Targets Ther，2017，10：5137-5149.
[15] Xu J，Zhang W，Lv Q，et al. Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN [J]. Oncol Rep，2015， 33（6）：3108-3116.
[16] Liu CH，Huang Q，Jin ZY，et al. miR-21 and KLF4 jointly augment epithelial-mesenchymal transition via the Akt/ERK1/2 pathway [J]. Int J Oncol，2017，50（4）：1109-1115.
[17] Zhang XF，Tu R，Li K，et al. Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer [J]. J Cell Biochem，2017，118（10）：3391-3400.
[18] Zhou X，Mao Y，Zhu J，et al. TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis [J]. Oncotarget，2016，7（41）：67196-67211.
[19] Wei RJ，Zhang CH，Yang WZ. MiR-155 affects renal carcinoma cell proliferation，invasion and apoptosis through regulating GSK-3β/β-catenin signaling pathway [J]. EurRev Med Pharmacol Sci，2017，21（22）：5034-5041.
[20] Zhao J，Feng Y，Yan H，et al. β-arrestin2/miR-155/GSK3β regulates transition of 5′-azacytizine-induced Sca-1-positive cells to cardiomyocytes [J]. J Cell Mol Med，2014， 18（8）：1562-1570.
[21] Feng Z，Xia Y，Zhang M，et al. MicroRNA-155 regulates T cell proliferation through targeting GSK3β in cardiac allograft rejection in a murine transplantation model [J]. Cell Immunol，2013，281（2）：141-149.